PURPOSE: This study aimed to evaluate whether a gelatin-based Gelfoam sponge is feasible as a scaffold for adipose tissue-derived stem cell (ASC) therapy in rat frozen-thawed ovarian autografts. METHODS: Two sets of studies were performed. The in vitro set evaluated ASCs' viability in the Gelfoam scaffold at different times of co-culturing (after 24, 48, 72, 96, and 120 h). The in vivo set used 20 12-week-old adult female Wistar rats. Frozen-thawed ovarian grafts were treated with ASCs delivered in Gelfoam scaffolds immediately after an autologous retroperitoneal transplant (ASCs-GS, n = 10). The controls received Gelfoam with a culture medium (GS, n = 10). Assessment of graft quality was conducted by vaginal smears (until euthanasia on the 30th postoperative day), histological analyses, follicular density, and viability and fibrosis. Immunohistochemical staining for VEGF-A expression, vascular network (vWF), apoptosis (caspase-3 and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)), cell proliferation (Ki-67), and hormone receptors (estrogen and progesterone) were performed. RESULTS: The cells remained viable in Gelfoam for up to 120 h of co-culturing. The graft morphology was similar among the groups. ASC therapy promoted the earlier resumption of the estrous phase (GS 16.6 ± 3 vs. ASCs-GS 12.8 ± 1.3 days) and enhanced estrogen receptors compared with the controls (p < 0.05) without interfering with the quantity and viability of the ovarian follicles, fibrosis, endothelial cells, VEGF immunoexpression, apoptosis, or cell proliferation (p > 0.05). CONCLUSION: The Gelfoam scaffold could be a feasible and safe non-invasive technique for ASC delivery in the treatment of frozen-thawed ovarian autografts. Future studies should evaluate the real benefit of this treatment on the survival and endocrine activity of the graft.
PURPOSE: This study aimed to evaluate whether a gelatin-based Gelfoam sponge is feasible as a scaffold for adipose tissue-derived stem cell (ASC) therapy in rat frozen-thawed ovarian autografts. METHODS: Two sets of studies were performed. The in vitro set evaluated ASCs' viability in the Gelfoam scaffold at different times of co-culturing (after 24, 48, 72, 96, and 120 h). The in vivo set used 20 12-week-old adult female Wistar rats. Frozen-thawed ovarian grafts were treated with ASCs delivered in Gelfoam scaffolds immediately after an autologous retroperitoneal transplant (ASCs-GS, n = 10). The controls received Gelfoam with a culture medium (GS, n = 10). Assessment of graft quality was conducted by vaginal smears (until euthanasia on the 30th postoperative day), histological analyses, follicular density, and viability and fibrosis. Immunohistochemical staining for VEGF-A expression, vascular network (vWF), apoptosis (caspase-3 and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)), cell proliferation (Ki-67), and hormone receptors (estrogen and progesterone) were performed. RESULTS: The cells remained viable in Gelfoam for up to 120 h of co-culturing. The graft morphology was similar among the groups. ASC therapy promoted the earlier resumption of the estrous phase (GS 16.6 ± 3 vs. ASCs-GS 12.8 ± 1.3 days) and enhanced estrogen receptors compared with the controls (p < 0.05) without interfering with the quantity and viability of the ovarian follicles, fibrosis, endothelial cells, VEGF immunoexpression, apoptosis, or cell proliferation (p > 0.05). CONCLUSION: The Gelfoam scaffold could be a feasible and safe non-invasive technique for ASC delivery in the treatment of frozen-thawed ovarian autografts. Future studies should evaluate the real benefit of this treatment on the survival and endocrine activity of the graft.
Authors: Heiko Methe; Helen M Nugent; Adam Groothuis; Philip Seifert; Mohamed H Sayegh; Elazer R Edelman Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Ariella Shikanov; Zheng Zhang; Min Xu; Rachel M Smith; Aniruddha Rajan; Teresa K Woodruff; Lonnie D Shea Journal: Tissue Eng Part A Date: 2011-09-21 Impact factor: 3.845
Authors: Juliana S Nakamuta; Maria E Danoviz; Fabio L N Marques; Leonardo dos Santos; Claudia Becker; Giovana A Gonçalves; Paula F Vassallo; Isolmar T Schettert; Paulo J F Tucci; Jose E Krieger Journal: PLoS One Date: 2009-06-23 Impact factor: 3.240
Authors: Luciana Lamarão Damous; Ana Elisa Teófilo Saturi de Carvalho; Juliana Sanajotti Nakamuta; Marcos Eiji Shiroma; Andressa Cristina Sposato Louzada; José Maria Soares-Jr; José Eduardo Krieger; Edmund C Baracat Journal: Stem Cell Res Ther Date: 2018-11-21 Impact factor: 6.832
Authors: Samara S Souza; Benner G Alves; Kele A Alves; Fabiana A S Brandão; Danielle C C Brito; Melba O Gastal; Ana P R Rodrigues; José R Figueireod; Dárcio I A Teixeira; Eduardo L Gastal Journal: PLoS One Date: 2020-11-04 Impact factor: 3.240